Across TCGA pan-cancer cohorts, ZNF564 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF564 data layer compared with 29 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF564 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF564 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC and ACC are the cancer types where ZNF564 Mutation most reproducibly stratifies survival.